Note sull'episodio
This week, we have conversations with Phil L'Huillier, CEO of Scancell, and Shai Melcer, head of Israel’s National Bio-Convergence Program.
Interview times:
03:25 Scancell
28:04 National Bio-Convergence Program
Scancell
Scancell recently announced a partnership with the UK’s NHS Cancer Vaccine Launch Pad, enabling fast-tracked access for melanoma patients.
The company’s DNA off-the-shelf cancer vaccine (iSCIB1+) is addressing a critical unmet need in advanced metastatic melanoma. It is currently in phase 2 clinical development with the next key data read outs expected in the middle of this year. Initial phase 2 clinical data showed ...
Parole chiave
biotechbiotechnologycancerScancellIsraelNational Bio-Convergence Programvaccinesbio-convergence